Overview
- 2 public-safe observations are available for this inspection.
- 2 structured CFR citations are represented.
- 2 investigators are tied to this Form 483.
Inspectional observations
Each observation cites the regulation FDA found the firm out of compliance with.
5 Apr 2019
21 CFR 211.160(a)
Lab controls established, including changes
Cited by Doan T Nguyen, Doan N Singh
5 Apr 2019
21 CFR 211.192
Investigations of discrepancies, failures
Cited by Doan T Nguyen, Doan N Singh
Inspected site
BIBoehringer Ingelheim Pharma GmbH and Co. KGBiberach An Der Ris, Germany
Inspection team
Cited regulations
CFR citations associated with this Form 483.
| Citation | What it covers | Cited |
|---|---|---|
| 21 CFR 211.160(a) | Cited across public-safe Form 483 observations | 1x |
| 21 CFR 211.192 | Cited across public-safe Form 483 observations | 1x |
Full 483 report
Get the verbatim text of all 2 observations
Every observation in full, so your team sees exactly what was cited and how it was answered.
- The site's full inspection history around this Form 483
- Whether these citations escalated to a warning letter
- The investigators involved and the citations they repeat elsewhere